The largest source of revenue in the life science automation and robotics market in 2024 will be the direct OEM sales channel, which will likely remain the highest-earning channel due to customers strong preference for fully integrated solutions, with vendor support in the form of robots. Life science organizations – especially pharma, biotech, and research institutions are interested in direct association with manufacturers to secure tailored automation arrangements, smooth hardware-software integration, and regulatory-compliant validation administration. Quick OEM delivery, continuous upgrades, and specialized technical services for high-value automation to support mission-critical processes like drug discovery, genomics, and bioprocess automation.
The automation integrators segment will experience high growth as organizations demand more hybrid, multi-vendor automation environments that cannot be achieved with single-OEM systems. System integrators focus on connecting robotics, AI-driven analytics, LIMS platforms, and legacy lab infrastructure to create end-to-end workflows. They are exceptionally well represented in biomanufacturing, QC automation, sample logistics, and lab digital transformation programs. Integrators are also considered important partners for regulatory documentation, validation, training, and cybersecurity; hence, they are important partners for the labs to modernize in phases, rather than replace the full system.
Value-added resellers have an increasing, though lower, presence in the life science automation and robotics market, which mostly serves mid-sized research labs, diagnostic facilities, and regional biotechs seeking affordable, pre-configured solutions. The VARs offer robotic instruments, installation services, workflow configurations, consumables, software packages, and services contracts, which simplify procurement for smaller organizations lacking automation expertise. They are strong in offering localized distribution, quicker delivery, and domain-specific application support.